TME Pharma Announces Strategic Update and €2.6 Million Financing Plan

TME Pharma N.V., a clinical-stage biotech company, has announced its strategy to secure €2.6 million in guaranteed financing. The funds will focus on completing strategic transactions or licensing for its compounds NOX-A12 and NOX-E36 by June 2025. This update includes a public offer restricted to shareholders, open from December 12 to 18, 2024.

The capital raise, without preferential subscription rights, is guaranteed by existing shareholders and a corporate partner. This approach ensures financial visibility until mid-2025 and aims to prioritize shareholders. Shareholders may subscribe on an irreducible basis during the priority period.

The financing proposal allows holders to buy five new shares for every four owned at €0.05 each, significantly discounted. TME Pharma aims to leverage the recent clinical success of NOX-A12, with plans for strategic transactions, and underscores a commitment to achieving long-term objectives.